US 11,911,359 B2
Stimulation of an immune response by cationic lipids
Weihsu Chen, Toronto (CA); Weili Yan, Auburn, AL (US); Kenya Johnson, Mason, OH (US); Gregory Conn, Madrid (ES); Frank Bedu-Addo, Bethel, CT (US); and Leaf Huang, Durham, NC (US)
Assigned to PDS Biotechnology Corporation, Cincinnati, OH (US)
Filed by PDS Biotechnology Corporation, North Brunswick, NJ (US)
Filed on Nov. 3, 2014, as Appl. No. 14/531,469.
Application 14/531,469 is a continuation of application No. 12/049,957, filed on Mar. 17, 2008, granted, now 8,877,206.
Claims priority of provisional application 60/983,799, filed on Oct. 30, 2007.
Claims priority of provisional application 60/948,512, filed on Jul. 9, 2007.
Claims priority of provisional application 60/911,549, filed on Apr. 13, 2007.
Claims priority of provisional application 60/896,412, filed on Mar. 22, 2007.
Prior Publication US 2015/0093410 A1, Apr. 2, 2015
Int. Cl. A61K 31/231 (2006.01); A61K 31/20 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 47/64 (2017.01); A61K 31/14 (2006.01); A61K 39/12 (2006.01); A61K 45/06 (2006.01); C07C 219/06 (2006.01)
CPC A61K 31/231 (2013.01) [A61K 31/14 (2013.01); A61K 31/20 (2013.01); A61K 39/00 (2013.01); A61K 39/0011 (2013.01); A61K 39/12 (2013.01); A61K 39/39 (2013.01); A61K 45/06 (2013.01); A61K 47/646 (2017.08); C07C 219/06 (2013.01); A61K 2039/55555 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A pharmaceutical formulation comprising a liposome together with at least one disease-associated antigen and a non-ionic buffer, wherein the liposome comprises one or more cationic lipids,
wherein the one or more cationic lipid consists of a quaternary cationic lipid, and
wherein the pharmaceutical formulation is free of phosphate buffered saline (PBS); and
wherein the disease-associated antigen is a protein or peptide.